The company states: “Cash and cash equivalents as of December 31, 2023 were $96.3 million. The company currently has over $81 million in cash and cash equivalents. Resource prioritization and cost reductions, including termination of the CAHmelia-203 clinical trial and a reduction in force of approximately 21%, extend cash runway through the end of 2025, including beyond anticipated topline results from CAHmelia-204 and additional dose-ranging data from CAHptain-205.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SPRB:
- SPRB Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Three new option listings on February 27th
- Spruce Biosciences price target raised to $9 from $8 at RBC Capital
- Guggenheim optimistic ahead of readouts, starts Spruce Biosciences at Buy
- Spruce Biosciences initiated with a Buy at Guggenheim